N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): A novel, selective KCNQ2/Q3 potassium channel activator

Molecular Pharmacology

Volumn 73, Issue 3, 2008, Pages 977-986

  Wickenden, A D ^a   Krajewski, Jeffrey L ^b   London, B ^b   Wagoner, P K ^b   Wilson, W A ^c   Clark, S ^d   Roeloffs, R ^b   McNaughton Smith, G ^b   Rigdon, G C ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Icagen Inc   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF WYOMING SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; CHLORIDE CHANNEL; LINOPIRDINE; N (6 CHLORO PYRIDIN 3 YL) 3,4 DIFLUORO BENZAMIDE; NEUROTRANSMITTER RECEPTOR; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KCNQ4; POTASSIUM CHANNEL KCNQ5; RUBIDIUM 86; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN SLICE; CELL MEMBRANE POTENTIAL; CHO CELL; DRUG IDENTIFICATION; ELECTRIC SHOCK; EMBRYO; EPILEPSY; EX VIVO STUDY; EXPERIMENTAL STUDY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN CELL; HYPERPOLARIZATION; IN VIVO STUDY; MALE; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SEIZURE; WHOLE CELL;

ANIMALS; BENZAMIDES; CELL CULTURE TECHNIQUES; CELL LINE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; HIPPOCAMPUS; HUMANS; INHIBITORY CONCENTRATION 50; KCNQ2 POTASSIUM CHANNEL; KCNQ3 POTASSIUM CHANNEL; KIDNEY; MALE; MEMBRANE POTENTIALS; MICROELECTRODES; NEUROBLASTOMA; PATCH-CLAMP TECHNIQUES; PLASMIDS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 40849085408     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.043216     Document Type: Article

References (38)

1. Aiken SP, Lampe BJ, Murphy PA, and Brown BS (1995) Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer. Br J Pharmacol 115:1163-1168.
2. Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, and Adín J (2005) Ion channels and epilepsy. Curr Pharm Des 11:1975-2003.
3. Bentzen BH, Schmitt N, Calloe K, Dalby Brown W, Grunnet M, and Olesen SP (2006) The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology 51:1068-1077.
4. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, and Steinlein OK (1998) A potassium channel mutation in neonatal human epilepsy. Science 279:403-406.
5. Biton V (2006) Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol 2:1009-1018.
6. Clark S and Wilson WA (1992) Brain slice model of epilepsy: Neuronal networks and actions of antiepileptic drugs, in Drugs for Control of Epilepsy: Actions of Neuronal Networks Involved in Seizure Disorders (CL Faingold and GH Fromm eds) pp 89-123, CRC Press, Boca Raton, FL.
7. Cooper EC, Harrington E, Jan YN, and Jan LY (2001) M channel KCNQ2 subunits are localized to key sites for control of neuronal network oscillations and synchronization in mouse brain. J Neurosci 21:9529-9540.
8. Delmas P and Brown DA (2005) Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 6:850-862.
9. 3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel? Eur J Pharmacol 412:203-212.
10. 2+ channels in clonal rat anterior pituitary cells (GH3/B6). Pflugers Arch 442:577-587.
11. Hadley JK, Noda M, Selyanko AA, Wood IC, Abogadie FC, and Brown DA (2000) Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels. Br J Pharmacol 129:413-415.
12. Kapetanovic IM, Yonekawa WD, and Kupferberg HJ (1995) The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro. Epilepsy Res 22:167-173.
13. Löscher W and Schmidt D (1994) Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res 17:95-134.
14. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, and Burbidge SA (2000) Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 58:253-262.
15. McNaughton-Smith GA, Gross MF, Wickenden AD (2000), inventors; Icagen, Inc., assignee. Benzanilides as potassium channel openers. U. S. Patent No. 6,372,767. 2002 April 16.
16. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, and Attali B (2005) Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol 67:1053-1066.
17. Peters HC, Hu H, Pongs O, Storm JF, and Isbrandt D (2005) Conditional transgenic suppression of M channels in mouse brain reveals functions in neuronal excitability, resonance and behavior. Nat Neurosci 8:51-60.
18. Porter RJ, Patriot A, Sachdeo R, Nohria V, and Alves WM (2007) Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 68:1197-1204.
19. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, Kutscher B, Löscher W, Honack D, White HS, et al. (1996) D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 23:211-223.
20. Rundfeldt C and Netzer R (2000a) Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 50:1063-1070.
21. Rundfeldt C and Netzer R (2000b) The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci Lett 282:73-76.
22. Schenzer A, Friedrich T, Pusch M, Saftig P, Jentsch TJ, Grotzinger J, and Schwake M (2005) Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci 25:5051-5060.
23. Schmidt D and Löscher W (2005) Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46:858-877.
24. Schrøder RL, Jespersen T, Christophersen P, Strobaek D, Jensen BS, and Olesen SP (2001) KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology 40:888-898.
25. Sills GJ, Rundfeldt C, Butler E, Forrest G, Thompson GG, and Brodie MJ (2000) A neurochemical study of the novel antiepileptic drug retigabine in mouse brain. Pharmacol Res 42:553-557.
26. Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, Bjerre I, Quattlebaum T, Murphy JV, et al. (1998) A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 18:25-29.
27. Stasheff SF, Anderson WW, Clark S, and Wilson WA (1989) NMDA antagonists differentiate epileptogenesis from seizure expression in an in vitro model. Science 245:648-651.
28. Tober C, Rostock A, Rundfeldt C, and Bartsch R (1996) D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 303:163-169.
29. Treiman DM (2001) GABAergic mechanisms in epilepsy. Epilepsia 42 (Suppl 3):8-12.
30. Turski WA, Cavalheiro EA, Bortolotto ZA, Mello LM, Schwarz M, and Turski L (1984) Seizures produced by pilocarpine in mice: a behavioral, electroencephalographic and morphological analysis. Brain Res 321:237-253.
31. van Rijn CM and Willems-van Bree E (2003) Synergy between retigabine and GABA in modulating the convulsant site of the GABAA receptor complex. Eur J Pharmacol 464:95-100.
32. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, Dixon JE, and McKinnon D (1998) KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 282:1890-1893.
33. Watanabe H, Nagata E, Kosakai A, Nakamura M, Yokoyama M, Tanaka K, and Sasai H (2000) Disruption of the epilepsy KCNQ2 gene results in neural hyperexcitability. J Neurochem 75:28-33.
34. Wickenden AD, Roeloffs R, McNaughton-Smith G, and Rigdon GC (2004) KCNQ potassium channels: drug targets for the treatment of epilepsy and pain. Expert Opin Ther Pat 14:457-469.
35. Wickenden AD, Yu W, Zou A, Jegla T, and Wagoner PK (2000) Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 58:591-600.
36. Wickenden AD, Zou A, Wagoner PK, and Jegla T (2001) Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 132:381-384.
37. Wong G, Lyon T, and Skolnick P (1994) Chronic exposure to benzodiazepine receptor ligands uncouples the gamma-aminobutyric acid type A receptor in WSS-1 cells. Mol Pharmacol 46:1056-1062.
38. Wuttke TV, Seebohm G, Bail S, Maljevic S, and Lerche H (2005) The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 67:1009-1017.